Prenetics Global Ltd (PRE) Financial

Prenetics Global Limited is a health sciences company, which engages in the provision of early detection, prevention, and treatment of cancer. The company employs 320 full-time employees. The company went IPO on 2021-07-06. The firm operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The firm's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The firm is also engaged in consumer health products by a new health and wellness brand IM8.